ID   LU-HNSCC-3
AC   CVCL_L178
SY   LU-HNSCC 3; LU-HNxSCC-3; HN-3
DR   IARC_TP53; 26988
DR   Wikidata; Q54903216
RX   PubMed=19216775;
CC   Doubling time: 1.8 +- 0.4 days (PubMed=19216775).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19216775).
DI   NCIt; C34447; Head and neck squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 21-03-23; Version: 11
//
RX   PubMed=19216775; DOI=10.1186/1756-9966-28-17;
RA   Henriksson E., Kjellen E., Baldetorp B., Bendahl P.-O., Borg A.,
RA   Brun E., Mertens F., Ohlsson T., Rennstam K., Wennerberg J.,
RA   Wahlberg P.;
RT   "Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2
RT   glucose uptake with proliferation parameters and gene expression in
RT   squamous cell carcinoma cell lines of the head and neck.";
RL   J. Exp. Clin. Cancer Res. 28:17.1-17.12(2009).
//